|
65675c55212eaade2e0cd408
|
2015
|
Sweden
|
Sida
|
2015900251
|
SE-0-SE-6-7500045801-GGG-12182
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0
|
0
|
0.0413642
|
0
|
0
|
0
|
0.0413642
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
EDCTP 2006-2015
|
EDCTP 2006-2015
|
The European and Developing Co...untries Clinical Trials Partnership, EDCTP includes 14 EU countries, Switzerland and Norway, and African countries. It joins European national research programmes and their African partnerships to develop new clinical tools (drugs, vaccines, diagnostics and microbicides) against HIV/AIDS, malaria and TB, with a focus on phase II and III clinical trials in SSA.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
21000
|
International NGOs
|
INTERNATIONAL NGO
|
|
|
|
65675c55212eaade2e0cd409
|
2015
|
Sweden
|
MFA
|
2015020118
|
UF2015-30475-UD-MU
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0237268
|
0.0237268
|
0
|
0
|
0.0237268
|
0.0237268
|
0
|
0.0237268
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
SUPPORT TO KAROLINSKA INSTITUT...E FOR THE IMPLEMENTATION OF A CONFERENCE ON HIV RESEARCH
more
|
SUPPORT TO KAROLINSKA INSTITUT...E FOR THE IMPLEMENTATION OF A CONFERENCE ON HIV RESEARCH
more
|
Support to Karolinska Institut...e for the implementation of a conference on HIV research
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Karolinska Institutet
|
|
|
|
65675c55212eaade2e0cd40a
|
2015
|
Sweden
|
Sida
|
2015900263
|
SE-0-SE-6-2150012801-AEA-12182
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0
|
0.0362311
|
0
|
0
|
0
|
0.0362311
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
SMI-TAMOVAC HIV VACCINE TRIALS... 2007-2013 - SMI-EDCTP VACCINE TRIAL
more
|
SMI-TAMOVAC HIV VACCINE TRIALS... 2007-2013 - SMI-EDCTP VACCINE TRIAL
more
|
The project aims to increase t...he capability to study HIV vaccines in Tanzania and Mozambique particularly among youths through continued evaluation of the HIVIS vaccines. These vaccines have been tested in a phase I trial in Sweden and are currently being tested in a phase I/II trial in Tanzania, HIVIS I, supported by Sida/SAREC
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65675c55212eaade2e0cd40b
|
2016
|
Sweden
|
Swedish International Developm...ent Authority
more
|
2015903831
|
SE-0-SE-6-5104002301-AEA-12182
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0
|
1.63618
|
0
|
0
|
0
|
1.63618
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
HEARD RESEARCH 2011-2017
|
HEARD research 2011-2017
|
Phase II support to HEARDs str...ategy 2011- 2015 Knowledge and Evidence for Impact: Integrating HIV Response with Human Development. The overall goal is: to contribute to the production of knowledge and utilisation of knowledge and evidence which support integrating health, HIV and human development responses in East and Southern Africa.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
UniversityCollegeResearchOther
|
|
|
|
65675c55212eaade2e0cd40c
|
2016
|
Sweden
|
Swedish International Developm...ent Authority
more
|
2015903972
|
SE-0-SE-6-5104006401-AEA-12182
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.11687
|
0
|
0
|
0
|
0.11687
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
REGIONAL HIV&SRHR RESEARCH PRO...GAM
more
|
Regional HIV&SRHR Research pro...gam
more
|
The Regional Research and Inno...vations Fund (RRIF) is a critical component of the 4 component regional HIV programme; Evidence for HIV Prevention in Southern Africa (EHPSA) developed by DFID. The EHPSA Programme aims to strengthen evidence for effective HIV preventative interventions among three selected populations: (i) young people (particularly adolescent women aged 10 to 24 years), (ii) prisoners and (iii) LGBTI. The research funded through the RRIF should help build an effective evidence base to mount a more innovative, effective and efficient prevention effort in the region. The EHPSA programme is therefore designed to take on a catalytic function in the region, to establish 'good practice' for evidence based HIV prevention and looks to disseminate findings which are also intended to influence the creation of favorable policy in the long-run. This intervention will be funded by DFID and Sida through a Delegated Partnership Arrangement where Sida will contribute 45 MSEK to this 100 MSEK intervention. Through this type of arrangement, DFID; the Lead donor will utilize its internal control mechanisms to implement this intervention through a Management Agent; HLSP-Mott MacDonald who were procured following rigorous selection process. This intervention will be implemented from 1st April 2014 through to 31st March 2018. Research institutions in the eastern and southern African region will be the awarding institutions to implement the research under the coordination of the management agent and it is foreseen that this intervention will be an opportunity for research institutions to develop capacity and strengthen partnerships to support the development and up to date maintenance of the regional evidence base. The intervention activities will include field testing of pilot programmes and the effective dissemination of findings two stages; mid-term in 2016 and full time dissemination in 2018.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
11000
|
Donor government
|
Donor Government
|
|
|
|
65675c55212eaade2e0cd40d
|
2018
|
Sweden
|
The Swedish Research Council
|
20160290050
|
2015-05914
|
3
|
Bangladesh
|
South & Central Asia
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.0437264
|
0
|
0
|
0
|
0.0437264
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
DEVELOPMENT OF A MOLECULAR SUR...VEILLANCE PHYLOGEOGRAPHIC TOOL TO TRACK HIV TRANSMISSION NETWORKS IN BANGLADESH
more
|
Development of a molecular sur...veillance phylogeographic tool to track HIV transmission networks in Bangladesh
more
|
AimsThe aim is to develop a co...st-effective molecular surveillance phylogeographic tool and use it to understand the intra- and inter-country movement of HIV strains in Bangladesh and inform on strategies how to combat the HIV epidemic. Three substudies will be done: i) To develop a near-full-length-genome protocol adopted for HIV strains in Bangladesh; ii) To develop a phylogeographic model for cluster analysis by integrating virus sequences with epidemiological, demographical and behavioural data, to understand the dynamics of transmission; iii) To validate and implement the model in Bangladesh to inform and support preventive measures.Project description and mode of cooperationThe KI researchers will develop two cost-effective and simplified tools: i) a full-genome sequencing assay (NFLG) based on modern next generation sequencing; ii) an high-resolution Bayesian phylogeographic model. By combining the methods, we will creat a powerful tool to understand the spatial and temporal movements of HIV. A larg number of plasma samples (n= 400) will be analysed from clients attending an HIV Testing and Counselling (HTC) services at Dhaka Hospital. The virus full-genome sequence data will be analysed together with epidemiological, demographical, and behavioural data. The design of the study is done together by the partners from KI and Bangladesh. The initial development of the assay and the phylogeopgraphic model will be done at KI. Thereafter the methods are transferred to
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Karolinska Institutet
|
|
|
|
65675c55212eaade2e0cd40e
|
2019
|
Sweden
|
The Swedish Research Council
|
20160290075
|
2015-03295_2
|
3
|
Ethiopia
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.0573716
|
0
|
0
|
0
|
0.0573716
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
RANDOMIZED CLINICAL TRIAL TO I...DENTIFY OPTIMAL PEDIATRIC EFAVIRENZ DOSAGE TO TREAT HIV INFECTED INFANT AND CHILDREN IN AFRICA
more
|
Randomized clinical trial to i...dentify optimal pediatric efavirenz dosage to treat HIV infected infant and children in Africa
more
|
More than 90% of the estimated... 3.3 million HIV infected children worldwide live in Sub Saharan Africa. Efavirenz (EFV) is approved recently by US-FDA and WHO as part of first line combination ART for HIV infected children >3 years of age. Based on results from few clinical studies, the US-FDA approved the use of EFV in infant and children aged =3 months weighing >3.5 kg. Due to lack of efficacy, safety and pharmacokinetic data WHO continues to limit the use of EFV in children under <3 years of age. The current body weight-based EFV dose recommended (FDA and WHO) to treat HIV in infant and children is scaled-down prediction from population pharmacokinetic modeling of data obtained from adult subjects treated with the standard maximum EFV dose. Biochemical and physiological processes between children and adults such as metabolism are disproportionate to their body weight differences. Although adult data is helpful to decide a first-in-children dose to initiate a safety, efficacy and PK study, the appropriate way to determine pharmacokinetic and pharmacodynamic parameters in children for a given age group is to conduct a dose optimization studies in specific age groups. Our extensive EFV dose optimization studies in Sub Saharan Africa patients indicate the importance of pharmacogenetic variations for efavirenz plasma exposure and treatment outcome. Based on population PK modeling of observational data, we demonstrated that standard 600 mg daily adult dose is unnecessarily high and recommended a dose reduction to 400 mg daily for adults in black African populations, which is confirmed by recent randomized clinical trials. In the present study we aim to perform a similar EFV dose optimization study specific for pediatrics population in Africa. EFV crosses the blood brain barrier and high plasma EFV concentration is associated with CNS toxicity, which may result in untoward effect for the developing child brain.We hypothesize that with the current recommended EFV dose, the risk of under- or overdosing of EFV is eminent among black African children who exhibit significant nutritional, comorbidity and host-genetic diversity from populations where pharmacokinetic and safety studies are performed and data extrapolated with one-dose-fit-all principle. We aim to identify safe and effective efavirenz dosage recommendations specific for pediatric use to treat HIV infected infants and children in Sub Saharan Africa. A three-phase extensive efavirenz pharmacokinetics, pharmacogenetics and pharmacodynamics based EFV dose optimization study will be conducted in HIV and HIV-TB co-infected infant and children from two genetically diverse African populations (Uganda and Ethiopia) during 2016 – 2020.First (Phase-1): observational study will be conducted to evaluate EFV plasma exposure, safety (skin rash, liver and CNS toxicity) and efficacy (immunologic and virological outcomes) of EFV based ART using the current EFV dose approved by FDA (< 3 years of age) and WH
more
|
|
12182
|
Medical research
|
3.b
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Karolinska Institutet
|
|
|
|
65675c55212eaade2e0cd40f
|
2018
|
Sweden
|
The Swedish Research Council
|
20160290052
|
2015-05842
|
3
|
Ethiopia
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.0448771
|
0
|
0
|
0
|
0.0448771
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
STRENGTHENING THE GRIP ON HIV ...IN ETHIOPIA - TRACING TRANSMISSION AND ANTIRETROVIRAL DRUG RESISTANCE IN THE ERA OF SCALING UP HIV CARE
more
|
Strengthening the grip on HIV ...in Ethiopia - tracing transmission and antiretroviral drug resistance in the era of scaling up HIV care
more
|
The overall purpose of this pr...oject is to strengthen the ongoing collaboration between the Ethiopian Public Health Institute (EPHI), Addis Ababa, Ethiopia and Lund University, Sweden. We outline a collaborative HIV research project, using technology and transfer from Sweden to enable laboratory assays and data analysis to be established and conducted at EPHI. The project also includes knowledge transfers and training opportunities for EPHI investigators in laboratory based investigations, sequence data management and analysis, and in disseminating research findings in international forums, with the aim of increasing scientific publications in peer-reviewed journals with EPHI scientists as first author. The partnership will allow us investigate patterns of antiretroviral drug resistance in Ethiopian human immunodeficiency virus (HIV) positive individuals – both before and during antiretroviral therapy (ART) – through virological, molecular epidemiology and socio-demographic characteristics. It will also allow us to extend our studies to include state-of-the art molecular epidemiology investigations of HIV to specifically address transmission routes between high-risk populations (female sex workers and long distance truck drivers) and the general population. This will be the first large-scale population study of antiretroviral drug resistance since the roll-out of ART in Ethiopia and it will provide valuable information on the current status of the HIV epidemic in the country.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Lunds universitet
|
|
|
|
65675c55212eaade2e0cd410
|
2019
|
Sweden
|
The Swedish Research Council
|
20160290074
|
2015-03295_1
|
3
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.0573716
|
0
|
0
|
0
|
0.0573716
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
RANDOMIZED CLINICAL TRIAL TO I...DENTIFY OPTIMAL PEDIATRIC EFAVIRENZ DOSAGE TO TREAT HIV INFECTED INFANT AND CHILDREN IN AFRICA
more
|
Randomized clinical trial to i...dentify optimal pediatric efavirenz dosage to treat HIV infected infant and children in Africa
more
|
More than 90% of the estimated... 3.3 million HIV infected children worldwide live in Sub Saharan Africa. Efavirenz (EFV) is approved recently by US-FDA and WHO as part of first line combination ART for HIV infected children >3 years of age. Based on results from few clinical studies, the US-FDA approved the use of EFV in infant and children aged =3 months weighing >3.5 kg. Due to lack of efficacy, safety and pharmacokinetic data WHO continues to limit the use of EFV in children under <3 years of age. The current body weight-based EFV dose recommended (FDA and WHO) to treat HIV in infant and children is scaled-down prediction from population pharmacokinetic modeling of data obtained from adult subjects treated with the standard maximum EFV dose. Biochemical and physiological processes between children and adults such as metabolism are disproportionate to their body weight differences. Although adult data is helpful to decide a first-in-children dose to initiate a safety, efficacy and PK study, the appropriate way to determine pharmacokinetic and pharmacodynamic parameters in children for a given age group is to conduct a dose optimization studies in specific age groups. Our extensive EFV dose optimization studies in Sub Saharan Africa patients indicate the importance of pharmacogenetic variations for efavirenz plasma exposure and treatment outcome. Based on population PK modeling of observational data, we demonstrated that standard 600 mg daily adult dose is unnecessarily high and recommended a dose reduction to 400 mg daily for adults in black African populations, which is confirmed by recent randomized clinical trials. In the present study we aim to perform a similar EFV dose optimization study specific for pediatrics population in Africa. EFV crosses the blood brain barrier and high plasma EFV concentration is associated with CNS toxicity, which may result in untoward effect for the developing child brain.We hypothesize that with the current recommended EFV dose, the risk of under- or overdosing of EFV is eminent among black African children who exhibit significant nutritional, comorbidity and host-genetic diversity from populations where pharmacokinetic and safety studies are performed and data extrapolated with one-dose-fit-all principle. We aim to identify safe and effective efavirenz dosage recommendations specific for pediatric use to treat HIV infected infants and children in Sub Saharan Africa. A three-phase extensive efavirenz pharmacokinetics, pharmacogenetics and pharmacodynamics based EFV dose optimization study will be conducted in HIV and HIV-TB co-infected infant and children from two genetically diverse African populations (Uganda and Ethiopia) during 2016 – 2020.First (Phase-1): observational study will be conducted to evaluate EFV plasma exposure, safety (skin rash, liver and CNS toxicity) and efficacy (immunologic and virological outcomes) of EFV based ART using the current EFV dose approved by FDA (< 3 years of age) and WH
more
|
|
12182
|
Medical research
|
3.b
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Karolinska Institutet
|
|
|
|
65675c55212eaade2e0cd411
|
2018
|
Sweden
|
The Swedish Research Council
|
20160290049
|
2015-05864
|
3
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.0437264
|
0
|
0
|
0
|
0.0437264
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
FACING NEW HEALTH CHALLENGES: ...THE ROLE OF HIV INFECTION AND THE RISK OF CARDIOVASCULAR DISEASE IN A HIGH-BURDEN HIV POPULATION IN UGANDA
more
|
Facing new health challenges: ...The role of HIV infection and the risk of cardiovascular disease in a high-burden HIV population in Uganda
more
|
People living with HIV have a ...higher risk of cardiovascular diseases (CVD) compared with HIV-negative individuals, possibly linked to low-grade, long-term inflammation. With the substantial increase in antiretroviral treatment in Sub-Saharan Africa in recent years, the mean age of people living with HIV is rising, and with it the risk of CVD. This is especially important since there also seems to be a genetic predisposition to CVD in Sub-Saharan Africa. In the Rakai population-based, open cohort in Uganda, data collection with almost yearly HIV tests has been ongoing since 1994 in ca 50 villages. This offers an excellent opportunity to estimate the risk of CVD in an HIV high-burden population using surveys, risk scores, anthropometric data, verbal autopsies and finally the Arteriograph armcuff to measure aortic stiffness as a proxy of early cardiovascular risk. The results from the planned studies with accurate data on onset of HIV infection, will not only help estimate the CVD risk, but also provide new insight into the pathophysiological process of development of atherosclerosis and duration of HIV infection. Starting off with this four-year project, the Karolinska and the Rakai teams, aim to develop a long-term common research agenda. Workshops and seminars will be held at both sites for this purpose, and joint publications as well as joint supervision of Master/PhD students are being planned. The project will be led by Helena Nordenstedt and Fred Nalugoda, respectively.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Karolinska Institutet
|
|
|
|
65675c56212eaade2e0cd412
|
2019
|
Sweden
|
The Swedish Research Council
|
20170290047
|
2016-05706
|
3
|
Ethiopia
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.0423016
|
0
|
0
|
0
|
0.0423016
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
A KNOWLEDGE TRANSLATION THROUG...H COMPLEX INTERVENTIONS - IMPROVING HEALTH AND CARE FOR CHILDREN AND ADOLESCENTS LIVING WITH LONG-TERM ILLNESSES IN ETHI
more
|
A knowledge translation throug...h complex interventions - Improving health and care for children and adolescents living with long-term illnesses in Ethi
more
|
We aim to develop and evaluate... models of complex interventions to improve the health of children and adolescents. The collaboration has two components; a course in complex interventions and two research studies focusing on children and adolescents living with HIV in Ethiopia. The project will build on an integrative synthesis of previous and ongoing research projects using a framework for complex interventions. The training will focus on translating knowledge and skills from well experienced Swedish and Ethiopian scholars to different collaboration projects building on the fruitful collaborations between Lund University and Addis Ababa University but include additional universities in Ethiopia and Iceland. The course will be delivered in workshops and seminars, alternating between Swedish and Ethiopian institutions and thereby forming a knowledge translation between different contexts in both countries. Two complex interventions will proceed during the three- year period; the effectiveness of interactive text messaging in improving compliance to care among children and adolescents receiving HIV treatment. The collaboration includes competences from three countries including a wide range of scientific disciplines and will result in 6-12 collaborating research projects that will enhance the possibilities for a mutual multi-scientific long-term collaboration in research for improving children's and adolescents' health in low income countries.
more
|
|
12182
|
Medical research
|
3.b
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Lunds universitet
|
|
|
|
65675c56212eaade2e0cd413
|
2019
|
Sweden
|
The Swedish Research Council
|
20170290061
|
2016-05762
|
3
|
Kenya
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.126905
|
0
|
0
|
0
|
0.126905
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
HORMONAL CONTRACEPTIVE USE AFF...ECTS HIV SUSCEPTIBILITY: DETERMINATION OF MECHANISMS AND PROPOSAL FOR THERAPEUTIC INTERVENTION
more
|
Hormonal contraceptive use aff...ects HIV susceptibility: determination of mechanisms and proposal for therapeutic intervention
more
|
Aim: HIV still causes a devast...ating global epidemic. Unfortunately, the risk of HIV infection seems to increase with the use of progesterone-based hormonal contraceptives, which is used by more than 50 million women. There is thus an urgent need to determine molecular mechanisms underlying this increased risk and propose therapeutic interventions. The same progesterone-related effect is also seen during the luteal phase of the menstrual cycle, a phase also associated with higher infection risk. We here hypothesize that local treatment with the sex hormone estrogen can contribute to a more HIV-resistant mucosal genital barrier. Work plan: Samples from the female reproductive tract have been collected from a Kenyan cohort of hormonal contraceptive-using women, and of women during their menstrual cycle. Newly developed digitalized imaging techniques and high-throughput proteomics techniques will be used to analyze mucosal factors associated with progesterone levels. Proof-of-concept experiments assessing progesterone and estrogen for their capacity to reduce HIV replication will thereafter be pursued in a genital mucosal explants model. Relevance: We aim to define mucosal factors influenced by sex hormones and explore whether this knowledge can be translated to a medication that can limit sexual HIV acquisition. Underprivileged women living in HIV-endemic areas with no options of contraceptive alternatives will thereby benefit from these scientific achievements.
more
|
|
12182
|
Medical research
|
5;3.b
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Karolinska Institutet
|
|
|
|
65675c56212eaade2e0cd414
|
2020
|
Sweden
|
The Swedish Research Council
|
2019290054
|
2019-04596
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.189466
|
0
|
0
|
|
0.189466
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
ADVERSE EFFECTS OF PRE-EXPOSUR...E PROPHYLAXIS AGAINST HIV ON MUCOSAL IMMUNOLOGY IN MALE ADOLESCENTS
more
|
Adverse effects of pre-exposur...e prophylaxis against HIV on mucosal immunology in male adolescents
more
|
One key area of impact for HIV... prevention is HIV pre-exposure prophylaxis (PrEP), a potentially life-saving and cost-effective intervention to treat individuals during high risk periods of their life. Considering that PrEP has been proven to be an effective measure to prevent HIV infection it is expected that its use will soon increase in African countries which have a high incidence of HIV infection among adolescents and adults.The applicant and co-applicants participate in an EDCTP funded project (CHAPS, 2018-2021), which is the first multi-country dosing/regime efficacy study for on-demand PrEP in two African countries, Uganda and South Africa. The CHAPS budget covers some laboratory work to be conducted with valuable foreskin specimens collected through the study. More funds are however needed to maximize the laboratory work and we hope in support from this VR call:To measure inflammation cytokines and tight junctions' integrity in foreskins upon PrEP administration in vivo.To evaluate the possible perturbation of inflammation genes and pathways upon ex vivo PEP exposure of foreskin.The proposed studies are novel and will contribute significantly to address knowledge gaps in the PrEP field.HIV negative men (n=112) (13- 29 years) will be recruited from clinics in South Africa (n=56) and Uganda (n=56). The laboratory work of this application will take place at the Karolinska Institutet and Imperial college of London in collaboration with a partner in Uganda.
more
|
0
|
12250
|
Infectious disease control
|
3.3
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Karolinska Institutet
|
|
|
|
65675c56212eaade2e0cd415
|
2020
|
Sweden
|
The Swedish Research Council
|
2019290068
|
2019-05235_1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.094154
|
0
|
0
|
|
0.094154
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
VIRAL AND EPIDEMIOLOGICAL FACT...ORS ASSOCIATED WITH TRANSMISSION OF HIV DRUG RESISTANCE
more
|
Viral and epidemiological fact...ors associated with transmission of HIV drug resistance
more
|
The global expansion of antire...troviral treatment (ART) is one of the greatest public health interventions ever undertaken. However, the emergence and spread of drug-resistant viral variants constitutes an imminent threat to the global roll-out of ART.This project is based on large representative cohorts from different parts of Ethiopia, the second most populous nation in Africa, and includes both HIV-positive subjects and individuals at high risk of HIV acquisition. Longitudinal follow-up and access to epidemiological and clinical data, as well as genetic information of the virus, will reveal new information on how viral, socio-demographic and behavioral factors interact in HIV transmission, with particular regard to drug-resistant variants. This knowledge will elucidate mechanisms of drug resistance development, and will be of direct use for the modification of ART programs. Moreover, the characterization of HIV transmission in the general population and high-risk groups, based on both viral and detailed epidemiological and behavioural factors, will provide new insights of how drug-resistant HIV strains disseminate.The results of this project will have direct impact for ART programs in Ethiopia and for similar settings in the world, where HIV-1 subtype C is dominant.
more
|
0
|
13040
|
STD control including HIV/AIDS
|
3.3
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Lunds universitet
|
|
|
|
65675c56212eaade2e0cd416
|
2020
|
Sweden
|
The Swedish Research Council
|
2019290069
|
2019-05235_2
|
3
|
Ethiopia
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.094154
|
0
|
0
|
|
0.094154
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
VIRAL AND EPIDEMIOLOGICAL FACT...ORS ASSOCIATED WITH TRANSMISSION OF HIV DRUG RESISTANCE
more
|
Viral and epidemiological fact...ors associated with transmission of HIV drug resistance
more
|
The global expansion of antire...troviral treatment (ART) is one of the greatest public health interventions ever undertaken. However, the emergence and spread of drug-resistant viral variants constitutes an imminent threat to the global roll-out of ART.This project is based on large representative cohorts from different parts of Ethiopia, the second most populous nation in Africa, and includes both HIV-positive subjects and individuals at high risk of HIV acquisition. Longitudinal follow-up and access to epidemiological and clinical data, as well as genetic information of the virus, will reveal new information on how viral, socio-demographic and behavioral factors interact in HIV transmission, with particular regard to drug-resistant variants. This knowledge will elucidate mechanisms of drug resistance development, and will be of direct use for the modification of ART programs. Moreover, the characterization of HIV transmission in the general population and high-risk groups, based on both viral and detailed epidemiological and behavioural factors, will provide new insights of how drug-resistant HIV strains disseminate.The results of this project will have direct impact for ART programs in Ethiopia and for similar settings in the world, where HIV-1 subtype C is dominant.
more
|
0
|
13040
|
STD control including HIV/AIDS
|
3.3
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Lunds universitet
|
|
|
|
65675c56212eaade2e0cd417
|
2020
|
Sweden
|
The Swedish Research Council
|
2019290059
|
2019-04741
|
3
|
Kenya
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.043432
|
0
|
0
|
|
0.043432
|
0
|
0
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
A NOVEL SWEDISH-KENYAN NETWORK... TO UNCOVER BIOLOGICAL MECHANISMS OF HOW INJECTABLE HORMONAL CONTRACEPTIVES CAN INCREASE HIV INFECTION RISK
more
|
A novel Swedish-Kenyan network... to uncover biological mechanisms of how injectable hormonal contraceptives can increase HIV infection risk
more
|
We will here establish a Swed...ish-Kenyan network around a novel human genital explant model, aimed at a joint research project uncovering biological mechanisms of how injectable hormonal contraceptives can cause the unexpected side-effect of increased HIV infection risk. The experimental work using the explant model will take place in Nairobi, while the mRNA, protein and in situ analysis ('omics' analyses) will be performed in Stockholm. The subsequent bioinformatics and imaging analyses can be performed at both locations following a joint educational program. The explant model and the omics analyses thus form a unique and highly relevant platform for uncovering biological mechanisms of how hormonal contraceptives affect the female genital mucosa with regard to HIV susceptibility. The collaboration will involve student/scientist exchange programs, workshops, a doctoral education course, retreats and joint grant applications and publications. These activities are likely to form a basis for a long-term collaboration and are likely to attract funding from other sources since it can be incorporated in evaluations of basic science on mucosal immunology and sexually transmitted infections as well as of clinical trials of pre-exposure prophylactic compounds. This novel collaboration is thus clearly based on mutual benefit and include collaboration of equal value on a research idea of highest significance for women's reproductive health in resource-poor settings.
more
|
0
|
13020
|
Reproductive health care
|
3.7
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Karolinska Institutet
|
|
|
|
65675c56212eaade2e0cd418
|
2014
|
UNICEF
|
UNICEF
|
2014001397
|
2400/A0/04/012/002
|
8
|
Kenya
|
South of Sahara
|
Other LICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.123915
|
0.123915
|
0
|
0
|
0.123915
|
0.123915
|
0
|
10
|
1
|
11
|
Classified as not health-speci...fic activity
more
|
|
100
|
IR2: SOCIAL BUDGETING
|
IR2: SOCIAL BUDGETING
|
IR2: SOCIAL BUDGETING
|
|
43010
|
Multisector aid
|
|
IV.2. Other Multisector
|
|
|
|
|
|
|
65675c56212eaade2e0cd419
|
2014
|
Asian Development Fund
|
AsDF
|
2014002051
|
LN0281-KIR
|
3
|
Kiribati
|
Oceania
|
LDCs
|
ODA Loans
|
4
|
10
|
410
|
C01
|
0
|
0
|
0.0123538
|
0
|
0
|
0
|
0.0123538
|
0
|
0
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
CAUSEWAY
|
Causeway
|
Causeway
|
|
99810
|
Sectors not specified
|
|
IX. Unallocated / Unspecified
|
12000
|
Recipient government
|
|
|
|
|
65675c56212eaade2e0cd41a
|
2014
|
United Kingdom
|
BIS
|
2011800990
|
MC_U137686851
|
8
|
China (People's Republic of)
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.878351
|
0.878351
|
0
|
0
|
0.878351
|
0.878351
|
0
|
0.878351
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
CHINA BASED STUDIES (A1, A5, A...9)
more
|
China Based Studies (A1, A5, A...9)
more
|
China Based Studies (A1, A5, A...9)
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd41b
|
2014
|
United Kingdom
|
BIS
|
2011800872
|
G0800142/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.101961
|
0.101961
|
0
|
0
|
0.101961
|
0.101961
|
0
|
0.101961
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
STRUCTURAL AND FUNCTIONAL STUD...IES IN LENTIVIRUS RNA ENCAPSIDATION
more
|
Structural and functional stud...ies in lentivirus RNA encapsidation
more
|
Structural and functional stud...ies in lentivirus RNA encapsidation
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd41c
|
2014
|
United Kingdom
|
BIS
|
2011800901
|
G0802777/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.30606
|
0.30606
|
0
|
0
|
0.30606
|
0.30606
|
0
|
0.30606
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
MECHANISMS WITHIN THE ESCRT MA...CHINERY REQUIRED FOR HIV-1 BUDDING
more
|
Mechanisms within the ESCRT ma...chinery required for HIV-1 budding
more
|
Mechanisms within the ESCRT ma...chinery required for HIV-1 budding
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd41d
|
2014
|
United Kingdom
|
BIS
|
2011800940
|
G1001757/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.44135
|
0.44135
|
0
|
0
|
0.44135
|
0.44135
|
0
|
0.44135
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
A UNIVERSAL T CELL VACCINE FOR... HIV-1
more
|
A universal T cell vaccine for... HIV-1
more
|
A universal T cell vaccine for... HIV-1
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd41e
|
2014
|
Asian Development Fund
|
AsDF
|
2014001718
|
LN2826-VIE
|
3
|
Viet Nam
|
Far East Asia
|
LMICs
|
ODA Loans
|
4
|
10
|
410
|
C01
|
0
|
0.461317
|
0
|
0
|
0
|
0.461317
|
0
|
0
|
0
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
COMPREHENSIVE SOCIOECONOMIC UR...BAN DEVELOPMENT PROJECT IN VIET TRI, HUNG YEN AND DONG DANG
more
|
Comprehensive Socioeconomic Ur...ban Development Project in Viet Tri, Hung Yen and Dong Dang
more
|
The proposed Project will addr...ess critical urban development issues of Viet Tri, Hung Yen, and Dong Dang in northern Viet Nam along the North-South economic corridor (NSEC), in contributing to the transformation of the NSEC from transport corridor into full-fledged economic corridor and in complementing Hanoi as alternative growth centers.
more
|
|
43030
|
Urban development and manageme...nt
more
|
|
IV.2. Other Multisector
|
12000
|
Recipient government
|
|
|
|
|
65675c56212eaade2e0cd41f
|
2014
|
Asian Development Fund
|
AsDF
|
2014001719
|
LN2826-VIE
|
3
|
Viet Nam
|
Far East Asia
|
LMICs
|
ODA Loans
|
4
|
10
|
410
|
C01
|
0
|
3.69821
|
0
|
0
|
0
|
3.69821
|
0
|
0
|
0
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
COMPREHENSIVE SOCIOECONOMIC UR...BAN DEVELOPMENT PROJECT IN VIET TRI, HUNG YEN AND DONG DANG
more
|
Comprehensive Socioeconomic Ur...ban Development Project in Viet Tri, Hung Yen and Dong Dang
more
|
The proposed Project will addr...ess critical urban development issues of Viet Tri, Hung Yen, and Dong Dang in northern Viet Nam along the North-South economic corridor (NSEC), in contributing to the transformation of the NSEC from transport corridor into full-fledged economic corridor and in complementing Hanoi as alternative growth centers.
more
|
|
21010
|
Transport policy & administrat...ive management
more
|
|
II.1. Transport & Storage
|
12000
|
Recipient government
|
|
|
|
|
65675c56212eaade2e0cd420
|
2014
|
United Kingdom
|
BIS
|
2011800956
|
G1100684/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.510955
|
0.510955
|
0
|
0
|
0.510955
|
0.510955
|
0
|
0.510955
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
A CLINICAL TRIAL OF DEXAMETHAS...ONE TO REDUCE MORTALITY IN CRYPTOCOCCAL MENINGITIS
more
|
A clinical trial of dexamethas...one to reduce mortality in cryptococcal meningitis
more
|
A clinical trial of dexamethas...one to reduce mortality in cryptococcal meningitis
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd421
|
2014
|
UNFPA
|
UNFPA
|
2014002629
|
|
1
|
Mauritania
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0672038
|
0.0672038
|
0
|
0
|
0.0672038
|
0.0672038
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
DATA ON POPULATION AND DEVELOP...MENT
more
|
Output 12: Data on Population ...and Development
more
|
Mauritania - Nouakchott - Outc...ome 4: Strengthened national policies and international development agendas through integration of evidence-based analysis on population dynamics
more
|
Data on Population and Develop...ment
more
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
|
|
|
|
65675c56212eaade2e0cd422
|
2014
|
UNICEF
|
UNICEF
|
2014003812
|
6490/A0/04/001/003
|
8
|
Papua New Guinea
|
Oceania
|
LMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.005394
|
0.005394
|
0
|
0
|
0.005394
|
0.005394
|
0
|
0
|
1
|
2
|
Projects of reproductive healt...h
more
|
Reproductive health Other
|
100
|
MATERNAL HEALTH
|
MATERNAL HEALTH
|
MATERNAL HEALTH
|
|
12110
|
Health policy and administrati...ve management
more
|
|
I.2.a. Health, General
|
|
|
|
|
|
|
65675c56212eaade2e0cd423
|
2014
|
United States
|
AID
|
2014003813
|
76_33503
|
3
|
Congo
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.00803
|
0
|
0
|
0
|
0.00803
|
0
|
0
|
0
|
0
|
Sector-wide health programmes
|
Sector-wide health programmes ...Other
more
|
100
|
OTHER PUBLIC HEALTH THREATS
|
Other Public Health Threats
|
Address public health threats ...posed by infectious diseases not targeted elsewhere in the Framework as well as significant non-communicable health threats of major public health importance.
more
|
|
12220
|
Basic health care
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Donor Government
|
|
|
|
65675c56212eaade2e0cd424
|
2014
|
United States
|
AID
|
2014003825
|
76_33510
|
3
|
Paraguay
|
South America
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.33494
|
0
|
0
|
0
|
0.33494
|
0
|
0
|
0
|
0
|
Sector-wide health programmes
|
Sector-wide health programmes ...Other
more
|
100
|
OTHER PUBLIC HEALTH THREATS
|
Other Public Health Threats
|
Address public health threats ...posed by infectious diseases not targeted elsewhere in the Framework as well as significant non-communicable health threats of major public health importance.
more
|
|
12220
|
Basic health care
|
|
I.2.b. Basic Health
|
52000
|
Other
|
Other
|
|
|
|
65675c56212eaade2e0cd425
|
2014
|
United States
|
AID
|
2014003530
|
76_33137
|
1
|
Cambodia
|
Far East Asia
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.007745
|
0.002735
|
0
|
0
|
0.01549
|
0.00547
|
0
|
0
|
0
|
0.01549
|
Child health
|
Child health General
|
50
|
MATERNAL AND CHILD HEALTH
|
Maternal and Child Health
|
Increase the availability and ...use of proven life-saving interventions that address the major killers of mothers and children and improve their health and nutrition status, including effective maternity care and management of obstetric complications; prevention services including newborn care, routine immunization, polio eradication, safe water and hygiene, and micronutrients; improved maternal, infant and young child feeding; and treatment of life-threatening childhood illnesses.
more
|
|
13020
|
Reproductive health care
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
11000
|
Donor government
|
Donor Government
|
|
|
|
65675c56212eaade2e0cd426
|
2014
|
UNFPA
|
UNFPA
|
2014002487
|
|
1
|
Malawi
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.00084607
|
0.00084607
|
0
|
0
|
0.00084607
|
0.00084607
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
ANALYSIS ON POPULATION DYNAMIC...S
more
|
Output 13: Analysis on populat...ion dynamics
more
|
Malawi - Lilongwe - Outcome 4:... Strengthened national policies and international development agendas through integration of evidence-based analysis on population dynamics
more
|
Analysis on population dynami...cs
more
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
|
|
|
|
65675c56212eaade2e0cd427
|
2014
|
UNFPA
|
UNFPA
|
2014002379
|
|
1
|
Libya
|
North of Sahara
|
UMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0148347
|
0.0148347
|
0
|
0
|
0.0148347
|
0.0148347
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
DATA ON POPULATION AND DEVELOP...MENT
more
|
Output 12: Data on Population ...and Development
more
|
Libya - Tripoli - Outcome 4: S...trengthened national policies and international development agendas through integration of evidence-based analysis on population dynamics
more
|
Data on Population and Develop...ment
more
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
|
|
|
|
65675c56212eaade2e0cd428
|
2014
|
United Kingdom
|
BIS
|
2011801000
|
MC_U950097144
|
8
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
1.36282
|
1.36282
|
0
|
0
|
1.36282
|
1.36282
|
0
|
1.36282
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
BASIC SCIENCE PROGRAMME / MOLE...CULAR EPIDEMIOLOGY OF HIV INFECTION
more
|
Basic Science Programme / Mole...cular epidemiology of HIV Infection
more
|
Basic Science Programme / Mole...cular epidemiology of HIV Infection
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd429
|
2014
|
United Kingdom
|
BIS
|
2011801001
|
MC_U950097145
|
8
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
1.59492
|
1.59492
|
0
|
0
|
1.59492
|
1.59492
|
0
|
1.59492
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
BASIC SCIENCE PROGRAMME /RESEA...RCH AIMED AT DESIGNING AN EFFECTIVE HIV VACCINE
more
|
Basic Science Programme /Resea...rch aimed at designing an effective HIV vaccine
more
|
Basic Science Programme /Resea...rch aimed at designing an effective HIV vaccine
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd42a
|
2014
|
United Kingdom
|
BIS
|
2011801002
|
MC_U950097146
|
8
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0328637
|
0.0328637
|
0
|
0
|
0.0328637
|
0.0328637
|
0
|
0.0328637
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
HIV CARE RESEARCH PROGRAMME / ...ARROW TRIAL
more
|
HIV Care Research Programme / ...ARROW trial
more
|
HIV Care Research Programme / ...ARROW trial
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd42b
|
2014
|
United Kingdom
|
BIS
|
2011801003
|
MC_U950097147
|
8
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.781541
|
0.781541
|
0
|
0
|
0.781541
|
0.781541
|
0
|
0.781541
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
HIV CARE RESEARCH PROGRAMME / ...FOLLOW UP OF SLOW DISEASE PROGRESSORS AND OF INDIVIDUALS ON LONG TERM ART
more
|
HIV Care Research Programme / ...Follow up of slow disease progressors and of individuals on long term ART
more
|
HIV Care Research Programme / ...Follow up of slow disease progressors and of individuals on long term ART
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd42c
|
2014
|
UNFPA
|
UNFPA
|
2014002631
|
|
1
|
Mauritania
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.608941
|
0.608941
|
0
|
0
|
0.608941
|
0.608941
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
DATA ON POPULATION AND DEVELOP...MENT
more
|
Output 12: Data on Population ...and Development
more
|
Mauritania - Nouakchott - Outc...ome 4: Strengthened national policies and international development agendas through integration of evidence-based analysis on population dynamics
more
|
Data on Population and Develop...ment
more
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
|
|
|
|
65675c56212eaade2e0cd42d
|
2014
|
United Kingdom
|
BIS
|
2011801022
|
MC_UP_A910_1026
|
3
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.00823181
|
0.00823181
|
0
|
0
|
0.00823181
|
0.00823181
|
0
|
0.00823181
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
COSTOP TRIAL
|
COSTOP trial
|
COSTOP trial
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd42e
|
2014
|
United Kingdom
|
BIS
|
2011801023
|
MC_UP_A910_1112
|
8
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.206425
|
0.206425
|
0
|
0
|
0.206425
|
0.206425
|
0
|
0.206425
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
HIV CARE RESEARCH PROGRAMME / ...IMPROVING HEALTH SYSTEMS RESPONSE TO CHRONIC DISEASES IN AFRICA
more
|
HIV Care Research Programme / ...Improving Health Systems response to Chronic Diseases in Africa
more
|
HIV Care Research Programme / ...Improving Health Systems response to Chronic Diseases in Africa
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Developing country-based NGO
|
|
|
|
65675c56212eaade2e0cd42f
|
2014
|
UNFPA
|
UNFPA
|
2014002632
|
|
1
|
Mauritania
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0233668
|
0.0233668
|
0
|
0
|
0.0233668
|
0.0233668
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
ANALYSIS ON POPULATION DYNAMIC...S
more
|
Output 13: Analysis on populat...ion dynamics
more
|
Mauritania - Nouakchott - Outc...ome 4: Strengthened national policies and international development agendas through integration of evidence-based analysis on population dynamics
more
|
Analysis on population dynami...cs
more
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
|
|
|
|
65675c56212eaade2e0cd430
|
2014
|
Asian Development Fund
|
AsDF
|
2014001465
|
LN2501-INO
|
3
|
Indonesia
|
Far East Asia
|
LMICs
|
ODA Loans
|
4
|
10
|
410
|
C01
|
0
|
1.93772
|
0
|
0
|
0
|
1.93772
|
0
|
0
|
0
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
INTEGRATED CITARUM WATER RESOU...RCES MANAGEMENT INVESTMENT PROGRAM - PROJECT 1
more
|
Integrated Citarum Water Resou...rces Management Investment Program - Project 1
more
|
The Project's objective is to ...improve water availability and improve integrated water resources managment. The Project's scope are project and program management; IWRM; capacity building; support to water resources insfrastructure development and managment; water rights stregthening; disaster managment; environmental protection; development of information and decision support systems; stakeholder participation.
more
|
|
14015
|
Water resources protection
|
|
I.4. Water Supply & Sanitation
|
12000
|
Recipient government
|
|
|
|
|
65675c56212eaade2e0cd431
|
2014
|
United States
|
AID
|
2014003845
|
76_33512
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.03587
|
0.05539
|
0
|
0
|
0.03587
|
0.05539
|
0
|
0
|
0
|
0.03587
|
Sector-wide health programmes
|
Sector-wide health programmes ...Other
more
|
100
|
OTHER PUBLIC HEALTH THREATS
|
Other Public Health Threats
|
Address public health threats ...posed by infectious diseases not targeted elsewhere in the Framework as well as significant non-communicable health threats of major public health importance.
more
|
|
12220
|
Basic health care
|
|
I.2.b. Basic Health
|
52000
|
Other
|
Other
|
|
|
|
65675c56212eaade2e0cd432
|
2015
|
UNICEF
|
UNICEF
|
2015004496
|
3920/A0/06/102/001
|
8
|
Somalia
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0572169
|
0.0572169
|
0
|
0
|
0.0572169
|
0.0572169
|
0
|
10
|
1
|
11
|
Child health
|
Nutrition
|
100
|
2.1. BNSP FACILITY-BASED (SUPP...LY SIDE)
more
|
2.1. BNSP FACILITY-BASED (SUPP...LY SIDE)
more
|
2.1. BNSP FACILITY-BASED (SUPP...LY SIDE)
more
|
Basic Nutrition Services Packa...ge (BNSP)
more
|
12220
|
Basic health care
|
|
I.2.b. Basic Health
|
|
|
|
|
|
|
65675c56212eaade2e0cd433
|
2015
|
UNFPA
|
UNFPA
|
2015004849
|
|
3
|
Nigeria
|
South of Sahara
|
LMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0
|
0.14978
|
0
|
0
|
|
0.14978
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
DATA ON POPULATION AND DEVELOP...MENT
more
|
Output 12: Data on Population ...and Development
more
|
Nigeria - Abuja. Output 12: St...rengthened national capacity for production and dissemination of quality disaggregated data on population and development issues that allows for mapping of demographic disparities and socio-economic inequalities, and for programming in humanitarian settings
more
|
Data on Population and Develop...ment
more
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
UNFPA
|
|
|
|
65675c57212eaade2e0cd434
|
2015
|
UNICEF
|
UNICEF
|
2015004133
|
2040/A0/05/905/003
|
8
|
India
|
South & Central Asia
|
LMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0960376
|
0.0960376
|
0
|
0
|
0.0960376
|
0.0960376
|
0
|
10
|
1
|
11
|
Classified as not health-speci...fic activity
more
|
|
100
|
2.6 TEACHER EDUCATION &SUPPORT... SYSTEM
more
|
2.6 TEACHER EDUCATION &SUPPORT... SYSTEM
more
|
2.6 TEACHER EDUCATION &SUPPORT... SYSTEM
more
|
|
11182
|
Educational research
|
|
I.1.a. Education, Level Unspec...ified
more
|
|
|
|
|
|
|
65675c57212eaade2e0cd435
|
2015
|
UNFPA
|
UNFPA
|
2015004794
|
|
3
|
Niger
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0
|
0.132433
|
0
|
0
|
|
0.132433
|
|
|
|
|
Projects of reproductive healt...h
more
|
Sexual violence
|
100
|
MARGINALIZED GIRLS
|
Output 08: Marginalized girls
|
Niger - Niamey. Output 8: Incr...eased capacity of partners to design and implement comprehensive programmes to reach marginalized adolescent girls including those at risk of child marriage
more
|
Marginalized girls
|
16050
|
Multisector aid for basic soci...al services
more
|
|
I.6. Other Social Infrastructu...re & Services
more
|
|
|
UNFPA
|
|
|
|
65675c57212eaade2e0cd436
|
2015
|
UNICEF
|
UNICEF
|
2015003756
|
2040/A0/05/901/005
|
8
|
India
|
South & Central Asia
|
LMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.033035
|
0.033035
|
0
|
0
|
0.033035
|
0.033035
|
0
|
10
|
1
|
11
|
Sector-wide health programmes
|
Sector-wide health programmes ...Other
more
|
100
|
1.9 EVIDENCE AND POLICY
|
1.9 EVIDENCE AND POLICY
|
1.9 EVIDENCE AND POLICY
|
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
|
0
|
|
|
65675c57212eaade2e0cd437
|
2015
|
UNFPA
|
UNFPA
|
2015005026
|
|
3
|
Pakistan
|
South & Central Asia
|
LMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0
|
0.0406219
|
0
|
0
|
|
0.0406219
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
DATA ON POPULATION AND DEVELOP...MENT
more
|
Output 12: Data on Population ...and Development
more
|
Pakistan - Islamabad. Output 1...2: Strengthened national capacity for production and dissemination of quality disaggregated data on population and development issues that allows for mapping of demographic disparities and socio-economic inequalities, and for programming in humanitarian settings
more
|
Data on Population and Develop...ment
more
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
UNFPA
|
|
|
|
65675c57212eaade2e0cd438
|
2015
|
UNICEF
|
UNICEF
|
2015004838
|
2130/A0/07/311/009
|
8
|
Iraq
|
Middle East
|
UMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0716859
|
0.0716859
|
0
|
0
|
0.0716859
|
0.0716859
|
0
|
0
|
1
|
2
|
Classified as not health-speci...fic activity
more
|
|
100
|
EMERGENCY EFFECTIVENESS
|
EMERGENCY EFFECTIVENESS
|
EMERGENCY EFFECTIVENESS
|
|
43010
|
Multisector aid
|
|
IV.2. Other Multisector
|
|
|
|
|
|
|
65675c57212eaade2e0cd439
|
2015
|
United Kingdom
|
BIS
|
2015005522
|
BIS-MRC-15-0184
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
2.46509
|
0.718044
|
0
|
0
|
2.46509
|
0.718044
|
0
|
2.46509
|
0
|
0
|
Specific HIV interventions
|
HIV Research and Development
|
100
|
REACH: RECENT HIV INFECTION: E...RADICATION BY ACTIVATION OF THE HIV RESERVOIR: A PROOF OF CONCEPT TRIAL TOWARDS A CURE FOR HIV.
more
|
REACH: Recent HIV infection: E...radication by Activation of the HIV reservoir: A proof of concept trial towards a Cure for HIV.
more
|
Medical Research Council Trans...lational research award for a proof of concept new therapy for HIV
more
|
|
13040
|
Std control including hiv/aids
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
